Radotinib
![]() | |
Systematic (IUPAC) name | |
---|---|
4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyrazin-2-ylpyrimidin-2-yl)amino]benzamide | |
Clinical data | |
Trade names | Supect |
Identifiers | |
926037-48-1 | |
PubChem | CID 16063245 |
ChemSpider | 17222861 |
Chemical data | |
Formula | C27H21F3N8O |
530.50 g/mol | |
SMILES
| |
|
Radotinib (INN; trade name Supect), and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)[1] with resistance or intolerance of other tyrosine kinase Bcr-Abl inhibitors, such as patients resistant or intolerant to the drug Imatinib (Gleevec, Glivec).
Radotinib is being developed by Ilyang Pharmaceutical Co., Ltd of South Korea[2] and is co-marketed by Daewoong Pharmaceutical Co. Ltd, in South Korea.[3] Radotinib completed a multi-national Phase II clinical trial study in 2012[4] and in August 2011, Ilyang initiated a Phase III, multinational, multi-center, open-label, randomized study for first-line indication.[5] Its mechanism of action involves inhibition of the tyrosine kinase Bcr-Abl and of platelet-derived growth factor receptor (PDGFR).[6]
References
- ↑ Joanne Bronson, Amelia Black, T. G. Murali Dhar, Bruce A. Ellsworth, and J. Robert Merritt. "Radotinib (Anticancer)". Annual Reports in Medicinal Chemistry 48: 523–524. doi:10.1016/b978-0-12-417150-3.00028-4.
|chapter=
ignored (help) - ↑ http://www.ilyang.co.kr/english/rnd/rnd03.asp
- ↑ http://www.dailypharm.com/Users/News/EnglishNews.html?NewsID=3108&nStart=1023&mode=&searchValue=
- ↑ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4077080/
- ↑ https://clinicaltrials.gov/ct2/show/NCT01511289?term=radotinib&rank=1
- ↑ "Radotinib hydrochloride". NCI Drug Dictionary. National Cancer Institute.